Itay&Beyond is a neurotech company leveraging brain-on-a-chip technology for CNS drug discovery. Following successful proof-of-concept studies using patient-derived organoids from ASD and epilepsy, the platform targets a multibillion-dollar market. The company’s business model focuses on building a pipeline of novel, effective compounds for out-licensing to pharma via joint development agreements (JDAs), backed by a strong team and early traction.